Epizyme Inc (EPZM)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139

Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Srl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate.

Data based on most recent fiscal year report
Market Cap2.37 Billion Shares Outstanding91.07 Million Avg Volume1.137 Million
1-Yr BETA vs S&P TR1.358 Current Ratio7.2 Quick Ratio7.2
View SEC Filings from EPZM instead.

View recent insider trading info

Funds Holding EPZM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding EPZM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

8.2 Thousand total shares from 6 transactions

Exercise Derivative Conversion (M)

12.5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

POPS RICHARD F DIRECTOR AND CEO, ALKERMES PLC

  • Officer
  • Director
759,094 2020-03-26 1

BAZEMORE ROBERT B PRESIDENT & CEO

  • Officer
  • Director
254,371 2020-03-24 4

ROS MATTHEW SEE REMARKS

  • Officer
51,798 2020-03-24 4

AGARWAL SHEFALI CHIEF MEDICAL OFFICER

  • Officer
71,991 2020-03-24 7

BEAULIEU JOSEPH CORPORATE CONTROLLER

  • Officer
4,961 2020-03-24 5

TOMBESI PAOLO CHIEF FINANCIAL OFFICER

  • Officer
15,437 2020-03-24 5

MOTT DAVID M

  • Director
0 2020-03-16 7

BAY CITY CAPITAL LLC

BAY CITY CAPITAL MANAGEMENT V LLC

BAY CITY CAPITAL FUND V, L.P.

BAY CITY CAPITAL FUND V CO-INVESTMENT FUND, L.P.

  • 10% Owner
1,393,612 2020-03-16 0

ALLEN ANDREW R

  • Director
12,500 2020-03-16 2

GOLDFISCHER CARL

  • Director
  • 10% Owner
0 2020-03-11 1

CONROY KEVIN T PRESIDENT AND CEO

  • Officer
  • Director
1,084,287 2020-02-27 4

GOULD ROBERT J SEE REMARKS

  • Officer
  • Director
554,845 2020-02-19 0

LEGORRETA PABLO G.

RP MANAGEMENT, LLC

RPI FINANCE TRUST

  • Director
  • 10% Owner
9,166,667 2020-02-11 3

BARRIS PETER J

  • Director
0 2020-02-06 0

SANDELL SCOTT D

  • 10% Owner
0 2020-01-29 0

BASKETT FOREST

  • 10% Owner
0 2020-01-29 0

KERINS PATRICK J

  • 10% Owner
9,569,451 2019-12-09 0

RHODES JASON P

  • Director
4,934,687 2019-11-18 0

LEGORRETA PABLO G.

  • Director
0 2019-11-06 3

GIORDANO MICHAEL F

  • Director
0 2019-10-30 1

SEIDENBERG BETH C

  • Director
17,698,819 2019-10-29 2

BOGLE GRANT C.

  • Director
0 2019-09-02 2

RICHON VICTORIA

  • Director
0 2019-09-02 2

BATE KENNETH

  • Director
0 2019-07-18 1

BARRETT M JAMES

  • Director
0 2019-05-30 0

NEW ENTERPRISE ASSOCIATES 13 LP

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
0 2019-01-22 0

VISWANATHAN RAVI

  • 10% Owner
5,000,000 2018-10-17 0

GRAF SUSAN E CHIEF BUSINESS OFFICER

  • Officer
0 2018-02-09 0

FLEMING SUZANNE SVP

  • Officer
0 2018-02-09 0

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

  • 10% Owner
No longer subject to file 2017-11-06 0

NEW ENTERPRISE ASSOCIATES 13 LP

  • 10% Owner
No longer subject to file 2017-11-06 0

HO PETER TAI-CHING CHIEF DEVELOPMENT OFFICER

  • Officer
10,123 2017-10-24 0

SINGER ANDREW E. EVP & CFO

  • Officer
45,446 2017-08-09 0

COPELAND ROBERT A PRESIDENT OF RESEARCH AND CSO

  • Officer
31,538 2017-06-06 0

KOLLURI KRISHNA KITTU

  • 10% Owner
5,215,128 2016-12-19 0

WELLER HARRY R

  • 10% Owner
3,490,073 2016-10-31 0

DRANT RYAN D

  • 10% Owner
7,489,485 2015-06-05 0

GARBACZ STEPHEN PRINCIPAL ACCOUNTING OFFICER

  • Officer
13,073 2014-11-03 0

HEDRICK ERIC CHIEF MEDICAL OFFICER

  • Officer
429 2014-10-15 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

BEAULIEU JOSEPH - Officer CORPORATE CONTROLLER

2020-03-25 S 212 $15.28 d 4,961 4,961.00 direct

ROS MATTHEW - Officer SEE REMARKS

2020-03-25 S 1,243 $15.28 d 51,798 51,798.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-25 S 3,285 $15.28 d 254,371 254,371.00 direct

TOMBESI PAOLO - Officer CHIEF FINANCIAL OFFICER

2020-03-25 S 1,243 $15.28 d 15,437 15,437.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2020-03-25 S 1,243 $15.28 d 71,991 71,991.00 direct

TOMBESI PAOLO - Officer CHIEF FINANCIAL OFFICER

2020-03-24 A 1,690 a 16,680 15,437.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-24 A 73,409 a 73,409 254,371.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-24 J 79,167 d 333,333 254,371.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-24 A 113,393 a 250,656 254,371.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2020-03-24 A 1,575 a 73,234 71,991.00 direct

BEAULIEU JOSEPH - Officer CORPORATE CONTROLLER

2020-03-24 A 1,556 a 5,173 4,961.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-24 J 48,727 d 298,737 254,371.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-24 J 56,537 d 80,726 254,371.00 direct

ROS MATTHEW - Officer SEE REMARKS

2020-03-24 A 1,563 a 53,041 51,798.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-24 J 2,371 d 333,333 254,371.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-03-24 A 7,000 a 257,656 254,371.00 direct

ALLEN ANDREW R - Director

2020-03-16 M 12,500 d 0 12,500.00 direct

ALLEN ANDREW R - Director

2020-03-16 M 12,500 $9.33 a 12,500 12,500.00 direct

BEAULIEU JOSEPH - Officer CORPORATE CONTROLLER

2020-03-03 S 996 $22.18 d 3,617 3,617.00 direct

LEGORRETA PABLO G. - Director - > 10% Owner see footnotes

RP MANAGEMENT, LLC - Director - > 10% Owner see footnotes

RPI FINANCE TRUST - Director - > 10% Owner see footnotes

2020-02-11 A 2,500,000 $20.00 a 9,166,667 9,166,667.00 indirect

BEAULIEU JOSEPH - Officer CORPORATE CONTROLLER

2020-02-03 A 2,575 a 3,617 3,617.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2020-02-03 A 12,856 a 71,659 71,659.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-02-03 A 252,956 a 252,956 137,263.00 direct

TOMBESI PAOLO - Officer CHIEF FINANCIAL OFFICER

2020-02-03 A 11,688 a 14,990 14,990.00 direct

ROS MATTHEW - Officer SEE REMARKS

2020-02-03 A 56,213 a 56,213 51,478.00 direct

BAZEMORE ROBERT B - Director - Officer PRESIDENT & CEO

2020-02-03 A 52,595 a 137,263 137,263.00 direct

BEAULIEU JOSEPH - Officer CORPORATE CONTROLLER

2020-02-03 A 11,588 a 11,588 3,617.00 direct

AGARWAL SHEFALI - Officer CHIEF MEDICAL OFFICER

2020-02-03 A 61,834 a 61,834 71,659.00 direct

ROS MATTHEW - Officer SEE REMARKS

2020-02-03 A 11,688 a 51,478 51,478.00 direct

TOMBESI PAOLO - Officer CHIEF FINANCIAL OFFICER

2020-02-03 A 56,213 a 56,213 14,990.00 direct

Elevate your investments